"Barclays' thesis centers on a single underappreciated asset, boosting its 2034 Tryngolza estimate for severe hypertriglyceridemia to $4 billion in the U.S., supported by 'supportive' physician checks."
"The sHTG label targets a broad patient population, with Phase 3 CORE and CORE2 trials demonstrating up to 72% placebo-adjusted reduction in fasting triglycerides and an 85% reduction in acute pancreatitis events."
"Net product sales for Tryngolza hit $50 million in Q4 2025, a 56% sequential increase, with full-year 2025 sales of $108 million, demonstrating strong launch execution."
Ionis Pharmaceuticals has experienced a 137.52% gain over the past year, though it has pulled back 6.12% year-to-date. Currently trading near $72.70, it remains below its 52-week high of $86.74. Barclays has raised its price target for Ionis to $106, citing the potential of its treatment for severe hypertriglyceridemia (sHTG) as a key driver. The sNDA for olezarsen in sHTG has a PDUFA target date of June 30, 2026, indicating a near-term catalyst for growth.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]